Healthcare Resource List: Womb to Tomb (Cradle to Grave) 2023

GLP-1-based medications have changed the treatment of obesity by making substantial, sustained weight loss possible for many people. But as these medicines become more widely used, another question has become increasingly important: How much of the weight lost on a GLP-1 drug comes from muscle or other lean tissue—and can that loss be minimized? The evidence shows a nuanced answer. People taking semaglutide, tirzepatide and related incretin-based medicines generally lose much more fat than lean tissue . At the same time, absolute lean mass usually falls during substantial weight loss. Importantly, lean mass is not the same thing as skeletal muscle : DXA-based “lean mass” also includes water, organs and other non-fat tissues. Therefore, a finding that lean mass decreased does not automatically mean that the same amount of skeletal muscle was lost. Recent 2026 meta-analyses suggest that roughly one-quarter to one-third of total weight lost with incretin therapy may be classified as lean ...

GLP-1 2.0: The Next Generation of Obesity Drugs

- October 06, 2026

By Dr. Frank Yap, MD · One Day Media Network · Updated October 2026 · Data current to this date Quick Answer "GLP-1 2.0" is the second wave of obesity medicines built on semaglutide and tirzepatide. It improves on the first wave in five ways: more potency (retatrutide, a triple agonist, averaged 28.3% weight loss at 80 weeks in Lilly's TRIUMPH-1 trial), new mechanisms (amylin and glucagon), easier formats (daily pills already approved; monthly injections in Phase 3), better body composition , and lower prices . As of September 29, 2026, no next-generation injectable is approved yet : retatrutide's FDA filing is planned for Q1 2027 and CagriSema's FDA decision is expected in late 2026. Approved 2.0-era products today are the oral drugs (Wegovy pill, Foundayo) and high-dose Wegovy HD. Disclosure: This article is educational and is...

Dr William Makis Ivermectin Protocol 2026 – Complete Guide + Patient Outcomes

- October 05, 2026

Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: September 2026 Dr. William Makis MD (McGill Medicine, 110+ peer-reviewed publications) has treated a large volume of cancer patients using repurposed drugs since 2023 and has documented outcomes publicly on Substack and X. This continuously updated 2026 guide compiles Dr. Makis's latest protocols (from his Substack, X posts through 2026, and direct patient correspondence). We cross-reference his exact dosages, schedules, combinations, safety data, sourcing, and real patient outcomes (anonymized but verifiable on his channels). Important Disclaimer: This content is for educational purposes only and does not constitute medical advice. Ivermectin is used off-label for cancer treatment. Always consult with a knowledgeable physician whom you trust to manage your health. Individual results may vary. Do not self-medicate with ivermectin without proper bloodwork and medica...

Semaglutide vs Tirzepatide vs Retatrutide: Best Weight Loss Peptides in 2026

- October 06, 2026

Medically Reviewed by: Dr. Frank Yap, MD | Written by: OneDayMD Editorial Team | Published: March 2026 | Last updated: October 6, 2026 Quick Answer As of October 2026, tirzepatide (Zepbound) is the strongest FDA-approved option at about 20–21% average weight loss, ahead of semaglutide (Wegovy) at about 15% (20.7% at the new 7.2 mg dose). Retatrutide, a triple agonist, reached 28.3% at 80 weeks in Phase 3 but is not FDA-approved ; Lilly plans to file in Q1 2027. What changed in this update (Oct 2026): replaced pre-Phase-3 estimates with TRIUMPH-1/2/3 results; corrected retatrutide launch timing (not before late 2027); added Wegovy HD, the Wegovy pill, Foundayo and CagriSema context; removed claims sourced only from research-peptide vendors, forum posts and unverified preprints; added CEBM evidence tiers, FAQ and an AI-prompt guide. Contents At-a-glance comparison How the three work What the trials show (and don't) Retatrutide: status in October 2026 Muscle and lean...

GLP-1 Studies Explained: The Complete Evidence Guide (2026 Edition)

- October 05, 2026

OneDayMD Master Evidence Guide • Updated September 2026 Semaglutide, tirzepatide, oral GLP-1 medicines, retatrutide and the next generation of metabolic therapies have changed the obesity and cardiometabolic treatment landscape. But the phrase “GLP-1 drug” can hide major differences in mechanism, indication, dose, study population and clinical evidence. This master guide organizes the most important clinical trials into an ebook-style reference—from the landmark STEP and SURMOUNT obesity trials to SELECT , FLOW , SUMMIT , ESSENCE , OASIS 4 , ATTAIN-1 , TRIUMPH, SURPASS and the emerging CagriSema program. 2026 update: The field has moved beyond injections alone. Oral semaglutide (Wegovy tablets) and orforglipron (Foundayo) are now U.S. FDA-approved options for weight management, while higher-dose semaglutide (Wegovy HD) has also ...

How to Get Ivermectin in the US: Pharmacies, Legal Status & State-by-State Access (2026)

- September 18, 2026

Medically Reviewed by: OneDayMD Editorial Team | Last Updated: August 2026 An updated, evidence-based guide to ivermectin's federal and state legal status, how to obtain a prescription, which states allow pharmacist-dispensed or OTC access, and a directory of pharmacies that fill ivermectin prescriptions in the US. Quick Answer (AI & Search Summary) Ivermectin is still classified federally as a prescription-only drug for human use. It has not been reclassified as OTC by the FDA. However, five states — Arkansas, Idaho, Louisiana, Tennessee, and Texas — have passed laws letting pharmacists dispense it without a doctor's prescription, and roughly half a dozen more have active bills. Everywhere else, you need a prescription from a doctor, urgent care provider, or telehealth service. Individual pharmacists retain the right to decline to dispense or stock it even where state law allows it. Table of Contents Current Legal Status (Federal & State) State-by-...

Top Smart Glasses for the Visually Impaired (2026): eSight, Envision, OrCam & More

- September 27, 2026

Medically & Technically Reviewed by: OneDayMD Editorial Team | Originally Published: August 9, 2026 | Updated: September 2026 Quick Answer There is no single "best" smart glasses for visual impairment in 2026 — the right pick depends on how much usable vision remains. For low vision (residual central vision from macular degeneration, diabetic retinopathy, or Stargardt disease), medical-grade enhancers like eSight Go ($4,950) or Acesight VR digitally magnify and boost contrast. For blind or near-blind users, AI-interpretation glasses like Envision Glasses ($2,499), Ally Solos (from $399), or a clip-on OrCam MyEye 3 Pro (remaining dealer stock, $3,689–$4,490) read text and describe scenes aloud. The cheapest mainstream option is Meta's expanding AI-glasses lineup — Ray-Ban Meta, Meta Glasses (Adventurer/Fury), and Meta Glasses by Kylie — starting at $299, which isn't purpose-built for accessibility but has become a popular everyday alternative thanks t...

Fenbendazole Joe Tippens Protocol: A Step-by-Step Guide (2026)

- September 21, 2026

Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: September 2026 If you have been diagnosed with cancer, or have a loved one that is suffering from cancer, chances are you have heard about the Joe Tippens Cancer Protocol. The Fenbendazole Cancer Protocol has been gaining rapid interest over the past years following some fenbendazole advanced cancer success stories and a recent peer-reviewed publication, " Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients : Results from a Prospective Observational Cohort ( Anticancer Research 2026 )" We have seen tremendous demand for some sort of guide on how to use fenbendazole for cancer as there is also tremendous confusion both from the healthcare and non-healthcare communities. Joe Tippens founded the protocol (1) after he was told a s...

DMSO 101: Benefits, Uses, Dosage and Side Effects (2026)

- September 17, 2026

Quick Summary: DMSO (Dimethyl Sulfoxide) is a naturally occurring compound with decades of research behind its use as an anti-inflammatory, analgesic, and cellular-protective agent. FDA-approved for interstitial cystitis, it has been used off-label by athletes, physicians, and patients for musculoskeletal injuries, chronic pain, wound healing, and more. This guide covers what DMSO is, how it works, the evidence for its key uses, safety considerations, dosing guidance, and where to find practitioners who use it. All off-label uses are experimental. Consult a qualified healthcare provider before use. A Patient Story: From Lung Transplant List to Clear CT Scans In 2022, Erica Eyres, a vigorous fifty-six-year-old aerobics instructor who had struggled to breathe, was given “absolutely devastating” news: She might need a lung transplant. She had never smoked, ran cross-country track in high school, and was a personal trainer for years, but, by 2024, a transplant assessment was arranged. “I d...

Ivermectin, Fenbendazole and Mebendazole: A Peer-Reviewed Protocol for Cancer Treatment (2026 Update)

- September 09, 2026

Medically Reviewed by: OneDayMD Editorial Team | Last Updated: April 2026 In September 2024, a first-of-its-kind protocol utilizing ivermectin, fenbendazole, and mebendazole for cancer treatment was peer-reviewed and officially published in the Journal of Orthomolecular Medicine . Led by researchers Dr. Ilyes Baghli, Dr. Pierrick Martinez, and FLCCC's Dr. Paul Marik, the protocol applies antiparasitic drugs — originally developed to combat parasites — to cancer treatment, building on emerging preclinical and clinical evidence of their anticancer properties. This trio of repurposed drugs has been shown to disrupt the growth of cancer cells, particularly by targeting microtubules, the essential structures that allow cancer to multiply uncontrollably. What makes this protocol even more potent is the synergistic effect when these drugs are used together, creating a powerful new affordable weapon against cancer. Journal of Orthomolecular Medicine 2024 Targeting the Mitochondrial-Stem C...

Search This Blog

The Medical Advisor